The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo has become the largest ever recorded for this Ebola strain, with 1,502 confirmed cases and 473 deaths reported by the country’s communications ministry. The caseload now surpasses all previous Bundibugyo outbreaks combined, including those in Uganda in 2007 and the DRC in 2012, which had case fatality rates of 30 and 50 per cent respectively. Transmission remains concentrated in the eastern provinces of Ituri, North Kivu and South Kivu, but weekly infections have reached their highest levels since the outbreak was declared in May, according to the World Health Organization.

The Bundibugyo virus, a filovirus with fruit bats as its suspected natural reservoir, spreads through direct contact with infected animals or the bodily fluids of symptomatic individuals. Its incubation period of two to 21 days and early non-specific symptoms such as fever and fatigue frequently delay diagnosis, allowing chains of transmission to go undetected. No licensed vaccine or antiviral treatment exists for this strain, a gap that has complicated containment. The WHO assesses the risk as very high within the DRC due to sustained community transmission, and high in Uganda and neighbouring states because of cross-border mobility and links to previous outbreaks. Globally, the risk remains low, though imported cases in health workers have been confirmed in France and Uganda.

Viewed from Kampala, Uganda has reported 20 confirmed cases, including two deaths, but no community transmission. All 836 identified contacts have been traced, with a 100 per cent follow-up rate, and surveillance systems remain fully activated. Beijing has dispatched a second team of medical experts to Kinshasa, focusing on epidemiology, clinical treatment and health quarantine, following what the Chinese foreign ministry described as highly praised work by an initial team. The Africa Centres for Disease Control and Prevention has warned that the outbreak is accelerating faster than previous Ebola events, with contact tracing in the DRC improving from 25 to 83 per cent, a rise that partly reflects better community trust and stronger surveillance.

The WHO has announced the enrolment of the first patients into a clinical trial evaluating potential treatments specifically targeting the Bundibugyo virus. The trial, described by the WHO Regional Director for Africa as a major scientific milestone, could yield the first targeted therapy for this variant. The next factual milestone to watch is the release of preliminary safety and efficacy data from the trial, while response coordinators continue to monitor cross-border transmission dynamics and the expansion of laboratory testing capacity in the affected zones.